Immunopotentiators NNS I-NP I-KP 0,18
activate VBP I-VP I-KP 19,27
innate JJ I-NP I-KP 28,34
immunity NN I-NP I-KP 35,43
directly RB O O 44,52
(for JJ I-NP O 53,57
example, NN I-NP O 58,65
cytokines) NN I-NP O 67,77
or CC O O 78,80
through IN I-PP O 81,88
receptors NNS I-NP I-KP 109,118
(PRRs, VBP I-VP O 119,124
such JJ I-NP O 126,130
as IN I-PP O 131,133
those DT I-NP O 134,139
for IN I-PP O 140,143
bacterial JJ I-NP O 144,153
components). NN I-NP O 154,165

The DT I-NP O 167,170
receptors NNS I-NP I-KP 181,190
(TLRs) EX B-NP O 191,197
are VBP I-VP O 198,201
a DT I-NP O 202,203
family NN I-NP O 204,210
of IN I-PP O 211,213
PRRs NNP I-NP I-KP 214,218
that WDT B-NP O 219,223
are VBP I-VP O 224,227
an DT I-NP O 228,230
important JJ I-NP O 231,240
link NN I-NP O 241,245
between IN I-PP O 246,253
innate NN I-NP O 254,260
and CC O O 261,264
adaptive JJ I-NP O 265,273
immunity. NN I-NP O 274,282

Some DT I-NP O 284,288
studies NNS I-NP O 289,296
have VBP I-VP O 297,301
shown VBN I-VP O 302,307
that IN I-PP O 308,312
TLR NNP I-NP I-KP 313,316
ligands NNS I-NP I-KP 317,324
have VBP I-VP O 325,329
adjuvant JJ I-NP O 330,338
activity NN I-NP O 339,347
and CC O O 348,351
enhance VB I-VP O 352,359
antibody NN I-NP O 377,385
and CC O O 386,389
immune NN I-NP O 404,410
responses, NN I-NP O 411,420
especially RB O O 422,432
when WRB O O 433,437
they PRP I-NP O 438,442
are VBP I-VP O 443,446
combined VBN I-VP O 447,455
with IN I-PP O 456,460
delivery NN I-NP O 461,469
systems NNS I-NP O 470,477
that WDT B-NP O 478,482
promote VBP I-VP O 483,490
their PRP$ I-NP O 491,496
uptake NN I-NP O 497,503
and CC O O 504,507
delivery NN I-NP O 508,516
into IN I-PP O 517,521
cells NNS I-NP I-KP 541,546
[22â€“24]. VBP I-VP O 547,554

For IN I-PP O 556,559
clinical JJ I-NP I-KP 560,568
studies, NN I-NP I-KP 569,576
TLR9 NNP I-NP I-KP 578,582
is VBZ I-VP O 583,585
generally RB I-VP O 586,595
stimulated VBN I-VP I-KP 596,606
with IN I-PP O 607,611
synthetic JJ I-NP I-KP 612,621
oligodeoxynucleotides NNS I-NP I-KP 622,643
containing VBG I-VP O 644,654
one CD I-NP O 655,658
or CC O O 659,661
more JJR O O 662,666
unmethylated JJ I-NP I-KP 667,679
CpG NNP I-NP I-KP 680,683
dinucleotides. NN I-NP I-KP 684,697

In IN I-PP O 699,701
humans, NN I-NP O 702,708
CpG NNP I-NP I-KP 710,713
has VBZ I-VP O 714,717
been VBN I-VP O 718,722
used VBN I-VP O 723,727
as IN I-PP O 728,730
an DT I-NP O 731,733
adjuvant NN I-NP I-KP 734,742
for IN I-PP O 743,746
infectious JJ I-NP I-KP 747,757
disease NN I-NP I-KP 758,765
vaccination NN I-NP I-KP 766,777
[25,26] NN I-NP O 778,785
and CC O O 786,789
in IN I-PP O 790,792
the DT I-NP O 793,796
development NN I-NP I-KP 797,808
of IN I-PP I-KP 809,811
cancer NN I-NP I-KP 812,818
therapy NN I-NP I-KP 819,826
[27]. NN I-NP O 827,831

In IN I-PP O 833,835
a DT I-NP O 836,837
mouse NN I-NP I-KP 838,843
model, NN I-NP I-KP 844,849
CpG NNP I-NP I-KP 851,854
has VBZ I-VP O 855,858
also RB I-VP O 859,863
been VBN I-VP O 864,868
shown VBN I-VP O 869,874
to TO I-VP O 875,877
induce VB I-VP I-KP 878,884
T NNP I-NP I-KP 885,886
helper PRP B-NP I-KP 887,893
1 CD I-NP I-KP 894,895
(Th1) JJ I-NP O 896,901
immune NN I-NP O 902,908
responses, NN I-NP O 909,918
which WDT B-NP O 920,925
are VBP I-VP O 926,929
characterized VBN I-VP O 930,943
by IN I-PP O 944,946
the DT I-NP O 947,950
production NN I-NP I-KP 951,961
of IN I-PP I-KP 962,964
and CC O I-KP 971,974
the DT I-NP I-KP 975,978
generation NN I-NP I-KP 979,989
of IN I-PP I-KP 990,992
IgG2a NNP I-NP I-KP 993,998
[28,29]. NNP I-NP O 999,1006

Moreover, NNP I-NP O 1008,1016
a DT I-NP O 1018,1019
previous JJ I-NP O 1020,1028
study NN I-NP O 1029,1034
had VBD I-VP O 1035,1038
demonstrated VBN I-VP O 1039,1051
that IN I-PP O 1052,1056
different JJ I-NP O 1057,1066
liposomes NNS I-NP I-KP 1067,1076
with IN I-PP O 1077,1081
CpG NNP I-NP O 1082,1085
ODN NNP I-NP O 1086,1089
significantly RB O O 1090,1103
increased VBD I-VP O 1104,1113
cytokines NNS I-NP I-KP 1125,1134
and CC O O 1135,1138
augmented VBN I-VP I-KP 1139,1148
cell NN I-NP I-KP 1149,1153
mediated VBN I-NP I-KP 1154,1162
immune JJ I-NP I-KP 1163,1169
response NN I-NP I-KP 1170,1178
[30]. NN I-NP O 1179,1183

